Moreover, ACEIs/ARBs, statins, SGLT-2 inhibitors, and aldosterone receptor antagonists may play a crucial role in mitigating cardiovascular risk and morbidity in COVID-19 patients (Wehbe et al., 2020). This evidence concerns the gene NR3C2 and COVID-19.